Skip to main content

Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD

Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long-term follow up results from the ELEVATE-TN study, which investigated acalabrutinib plus or minus obinutuzumab for previously untreated patients with ...

Continue reading

Acalabrutinib in Chronic Lymphocytic Leukemia: Jeff Sharman, MD

​In patients with previously untreated chronic lymphocytic leukemia (CLL), the interim results of the phase 3 ELEVATE-TN trial have revealed that acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival, either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech). This study led to the recent FDA approval of acalabrutinib for CLL and small lymphocytic lymphoma (SLL). In this interview with i3 Health, Jeff P. Sharman, MD, the trial's principal investigator, di...

Continue reading

FDA Approves Acalabrutinib for CLL and SLL

The FDA has just granted supplemental approval to acalabrutinib (Calquence®, AstraZeneca) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main difference between CLL and SLL is where they occur in the body; CLL most often originates in the blood and bone marrow, and SLL occurs primarily in the lymph nodes. However, both of these diseases are cancers of lymphocytes—a type of immune cell that helps the body fight infection. Indications of CLL or SLL in...

Continue reading

Acalabrutinib, Alone or in Combination, Improves Progression-Free Survival in CLL

​In previously untreated chronic lymphocytic leukemia (CLL), acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech), according to interim results of the phase 3 ELEVATE-TN trial to be presented at the American Society of Hematology (ASH) Annual Meeting. Acalabrutinib, a highly selective, covalent irreversible Bruton tyrosine kinase inhibitor, is currently FDA approved for the treatment of relapsed ...

Continue reading